title: Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients.
abstract: Several factors are predictive of treatment-free remission (TFR) in chronic myeloid leukemia (CML), but few data exist on the role of natural killer (NK) cells and their killer-cell immunoglobulin-like receptors (KIRs). KIR and human leukocyte antigen (HLA) genotypes were investigated in 36 CML patients who discontinued tyrosine kinase inhibitor (TKI) treatment after achieving deep molecular response (MR(4.5)). Cumulative TFR was significantly higher in patients homozygous for KIR A haplotype (85.7% vs. 45.5%; p = 0.029). Younger age, Bx haplotype, and the combination KIR3DS1/KIR3DL1 present/HLA-Bw4 present were significantly associated with relapse. KIR genotypes could prove useful in identifying patients that are likely to maintain MR(4.5) after discontinuing TKI treatment.
authors: Hematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy. Electronic address: giovanni.caocci@unica.it.
authors: Giovanni
authors: G
authors: Caocci
authors: Division of Hematology, Ospedali Riuniti, Reggio Calabria, Italy.
authors: Bruno
authors: B
authors: Martino
authors: Hematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
authors: Marianna
authors: M
authors: Greco
authors: Hematology Unit, S. Eugenio Hospital, Tor Vergata University, Rome, Italy.
authors: Elisabetta
authors: E
authors: Abruzzese
authors: Hematology Unit, S. Eugenio Hospital, Tor Vergata University, Rome, Italy.
authors: Malgorzata Monika
authors: MM
authors: Trawinska
authors: Medical Genetics, Department of Medical Sciences, Regional Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
authors: Sara
authors: S
authors: Lai
authors: Medical Genetics, Department of Medical Sciences, Regional Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
authors: Paola
authors: P
authors: Ragatzu
authors: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
authors: Sara
authors: S
authors: Galimberti
authors: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
authors: Claudia
authors: C
authors: Baratè
authors: Hematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
authors: Olga
authors: O
authors: Mulas
authors: Division of Hematology, Ospedali Riuniti, Reggio Calabria, Italy.
authors: Claudia
authors: C
authors: Labate
authors: Medical Genetics, Department of Medical Sciences, Regional Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
authors: Roberto
authors: R
authors: Littera
authors: Medical Genetics, Department of Medical Sciences, Regional Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
authors: Carlo
authors: C
authors: Carcassi
authors: Department of Internal Medicine, University of Milano Bicocca, Monza, Italy.
authors: Carlo
authors: C
authors: Gambacorti Passerini
authors: Hematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
authors: Giorgio
authors: G
authors: La Nasa
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D054341:Receptors, KIR3DL1 / Q000276:immunology*; D054349:Receptors, KIR3DS1 / Q000276:immunology*; D015996:Survival Rate
chemical_list: C515083:KIR3DL1 protein, human; D047428:Protein Kinase Inhibitors; D054341:Receptors, KIR3DL1; D054349:Receptors, KIR3DS1